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Summary  
Human papillomavirus induced cutaneous warts are potentially serious and debilitating. In immuno-
suppressed patients these warts may be resistant to standard therapies. We report a case of a young 
patient with a primary immune deficiency whose recalcitrant cutaneous warts regressed completely 
following administration of the quadrivalent human papillomavirus vaccine.  
 
Introduction 
Cutaneous human papillomavirus infection is a common consequence of immune compromise in a 
variety of contexts, including inherited immune-deficiency, HIV infection and post-transplantation
1
. 
Cutaneous warts arise in up to 25% of immunosuppressed patients and often prove recalcitrant or 
refractory to numerous and prolonged treatments 
1
. Though usually benign, cutaneous warts cause 
symptoms related to the psychosocial effects of the disease, mechanical interference, pain and 
deterioration in functional abilities of patients. These symptoms and effects are exacerbated in cases 
where warts are widespread, thick or located on the hands, feet or face.  
 
Report 
We present a case in which persistent cutaneous HPV warts in an immune compromised patient 
completely resolved following vaccination with the quadrivalent HPV vaccine.   
A 17 year old male patient was referred to the immunology department of our hospital after an 
incidental finding of neutropaenia and lymphopaenia. This was uncovered during routine screening 
prior to consideration of isotretinoin treatment for facial acne vulgaris. Further investigation showed a 
persistent neutropaenia (0.6 x 10
9
/L) and a CD3 lymphopaenia (total: 1x10
9
/L, CD4: 129x10
6
, CD8: 
92x10
6
/L) which was diagnosed as idiopathic. He had normal T and B cell maturation, normal 
neutrophil respiratory burst, normal immunoglobulin levels and immunoglobulin sub-classes. His HIV 
serology was negative, he had normal autoimmune serology testing and maintained responses to 
previous vaccinations. He was given prophylaxis with co-trimoxazole 480mg daily. 
Other than more severe recurrent childhood infections than his peers, the patient had been systemically 
generally well. However he had a seven-year history of persistent hand (Fig. 1) and similar foot warts 
which had not resolved despite treatment with repeated cryotherapy, imiquimod and numerous over-
the-counter topical treatments. He was referred to the dermatology department in the same hospital for 
further review of his hands and feet. Though not extensive, the warts were persistent and caused 
significant impact on quality of life. The patient did not exhibit signs of atopy. 
The patient received the standard three dose course of Gardasil® quadrivalent papillomavirus vaccine. 
After the second dose of the vaccine, the warts began to regress and complete resolution of all warts 
was reported within weeks after the third vaccine dose (Fig. 2). There was no recurrence of the warts up 
to two years post vaccine. The patient experienced no adverse effects from the vaccination. 
Although there is evidence against the bivalent or quadrivalent vaccine having an effect on HPV 
disease in the cervix or on genital warts
9-10
, there is limited anecdotal evidence for the role of the 
vaccination as a therapy for cutaneous warts. Four individual case reports in immune competent 
individuals
4-7
 suffering from extensive cutaneous warts exist, in all cases the warts resolved following 
treatment with the HPV vaccine.  
In a more recent report
8
 an elderly patient with chronic lymphatic leukaemia in remission and 
lymphopaenia and neutropaenia following chemotherapy for breast cancer also experienced resolution 
of cutaneous warts following vaccination, though in that case the warts had been present prior to the 
immune suppression. To our knowledge, no reports exist of patients with innate or inherited immune 
suppression whose cutaneous warts have been treated with the HPV vaccine.  
A previously reported case also supports a potential role for HPV vaccination in cutaneous warts in the 
context of WHIM syndrome
2
. 
Though the resolution of warts in this patient following vaccination may be coincidence, the clinical 
course, timing and lack of effect of conventional treatments over many years argue against this.  
The mechanism by which vaccination against HPV types which are not the causative agent in 
cutaneous warts might have a therapeutic effect is unclear. There is similarity between the genomes of 
HPV 2 subtypes (27 and 57) and HPV 6 which may lead to cross-reactive immune responses. An 
alternative, or additional hypothesis might be that the quadrivalent vaccine or its adjuvant stimulates 
immune responses non-specifically leading to clearance via a generalised up-regulation of immunity. 
Furthermore there is evidence that prophylactic vaccination against HPV can stimulate responsive 
lymphocyte activation
3
 against virally infected cells, which may lead to targeted immune clearance. 
This patient exhibited a similar immune phenotype to that which might be expected in iatrogenic 
immunosuppression due to calcineurin inhibitors (i.e. for organ transplant recipients). No published 
evidence exists to date of the efficacy of HPV vaccination for treatment of cutaneous warts in such 
patients, but given the importance and size of that population future interventional studies would seem 
warranted. 
Human papillomavirus infection can lead to cutaneous warts which, in the immunosuppressed, can 
persist with significant impacts on quality of life. We present the first reported case of full resolution of 
HPV warts in a patient with idiopathic immune suppression following administration of the 
quadrivalent HPV vaccine. 
Learning Points 
 Cutaneous warts are potentially serious and debilitating 
 Cutaneous warts may be resistant to standard therapy in immune suppressed patients. 
 The quadrivalent HPV vaccine may be of potential benefit in these patients. 
Figure 1: Cutaneous hand warts at initial presentation of the patient.  
Figure 2: Cutaneous hand warts 6 months after the third dose of quadrivalent human 
papillomavirus vaccine. 
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